Shisha Is the Most Valuable Player for Thousands of Bars and Cafés – New Research Shows
25.10.2024 19:06:00 CEST | Business Wire | Press release
AIR Group Limited, the world’s largest producer of shisha molasses, owner of the famous Al Fakher brand and the inventor of the OOKA, the world’s first charcoal free pod-based shisha system, has released new research on the role of shisha in microbusinesses such as bars and cafés in the Middle East, Europe and the United States.
The study involved hundreds of interviews with bar, restaurant and café owners and managers in the UAE, Saudi Arabia, Germany, Spain and the US.
On average, circa 8 in 10 of the businesses surveyed identified shisha as the highest margin product item in their venues.
According to Ronan Barry, Chief Corporate Affairs Officer of AIR Group, “This shows us that shisha is among the most equitable fast moving consumer goods (aka FMCG’s) in the world. In most FMCG and lifestyle product categories the majority of the value accrues to the brand owner with some scraps left over for the broader value chain. But in shisha, the value is more equitably distributed with the lion’s share going to the smallest businesses in the chain, those who serve the experience to the consumer.”
“We have long suspected that shisha is likely the Most Valuable Player (MVP) in the hospitality sector. These businesses enjoy margins on shisha of up to 95%, compared to about 5% on average in food.”
There are over a hundred thousand hospitality venues serving shisha and according to the sample surveyed by AIR, if these businesses did not serve shisha, their very survival would be in doubt. Almost half of survey respondents would close their doors if they were unable to offer shisha.
According to Garth Beer, who manages a shisha catering business providing shisha service to dozens of bars, restaurants and night clubs, “Shisha plays a critical role in drawing customers into the venue and in keeping them there. In some cases, its ‘come for the shisha, stay for the food and drink’ while in others its ‘come for the food, stay for a shisha’ and that the after-dinner shisha can be the difference between a profitable table and a non-profitable table.”
However, the boom of shisha remains unavailable to a majority of bars and restaurants due to the use of charcoal to heat the molasses and generate the cloud for the customers to enjoy. Charcoal is both a fire hazard and a source of toxic chemicals in indoor environments, requiring significant investments in fire safety and ventilation. AIR’s newest innovation, a revolutionary charcoal free, pod-based shisha system offers the opportunity for more microbusinesses to reap the benefits of shisha services because it removes charcoal and side streams smoke entirely, leaving a much cleaner shisha cloud for the consumer to enjoy. Already OOKA has been embraced by almost 250 bars and restaurants in Germany and in the UAE.
According to Mario, General Manager of a premium night club in Dubai “We, regrettably, had to exclude shisha from our club due to the smoke and fire safety concerns even though guests have been asking for it.
“We’ve had OOKA for a few months now and the feedback from our customers is fantastic. We’re on track to have a record season and it’s clear that OOKA will be a major contributor to that.”
AIR will continue to work with hospitality businesses around the world to support them in adopting shisha and OOKA and also in supporting the training of their staff to ensure that they can confidently offer the best customer experience in every serving.
About AIR (ADVANCED INHALATION RITUALS)
AIR is the market leader in the $19 billion global shisha market, with an aim to provide superior physical, emotional and mental benefits through inhalation. Launched in 1999 and headquartered in Dubai, the business has a multinational presence in over 100 countries across the UAE, Europe, North America, India, and Africa.
AIR holds 47% of the shisha category market share in the markets it is present it and is the leading business in a market set to grow to $22 billion in 2026. Its portfolio of companies includes Al Fakher, the world’s leading shisha brand; Hookah-Shisha.com, the world’s number one e-commerce platform for hookahs and shisha; Shisha Kartel, a Dubai-based shisha manufacturer; and Shisha.com, a global online community of shisha and hookah users. Advanced Inhalation Rituals’ science program, conducted in partnership with independent accredited laboratories, enables the development innovative products that combine centuries of tradition with cutting edge innovation to minimise harm and maximise enjoyment for millions around the world. The business has consistently outperformed competitors growing at 3x the market rate over the last 10 years, due to heavy investment in innovation, product, and user experience.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241025730501/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom